Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006028 | 1.00 | TLR7 (0.44) | TLR7TLR8SMN1; SMN2HPGDKDM4E | |
| SCHEMBL3865322 | 0.93 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL5750020 | 0.92 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL4343043 | 0.90 | TLR7 (0.40) | TLR7TLR8ALDH1A1MAPT | |
| SCHEMBL7102928 | 0.88 | TLR7 (0.43) | TLR7 | |
| SCHEMBL6031144 | 0.85 | TLR7 (0.44) | TLR7 | |
| SCHEMBL5751136 | 0.84 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL6031989 | 0.84 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL4340474 | 0.83 | TLR7 (0.35) | TLR7TLR8 | |
| SCHEMBL7101492 | 0.83 | TLR7 (0.44) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200345842-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-05 | — | — | US | disclosed |
| US-10722573-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-07-28 | — | — | US | disclosed |
| CN-105126072-B | Compositions for stimulating innate immune resistance to pathogens in mammals | 德克萨斯大学系统董事会 | 2020-05-15 | — | — | CN | disclosed |
| EP-3538218-A2 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | The Board of Regents of The University of Texas System (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190269773-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-05 | — | — | US | disclosed |
| EP-2411521-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | The Board of Regents of The University of Texas System (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111485-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7115622-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-30 | — | — | US | disclosed |
| US-20040157874-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-08 | — | — | US | disclosed |
| US-6664265-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-6660747-B2 | Contain ether and amide functionality at the 1-position; useful as immune response modifiers and can induce biosynthesis of various cytokines; useful in treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885TLR8 51/4885SMN1; SMN2 3812/4885 |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885TLR8 51/4885SMN1; SMN2 3812/4885 |
| US-20040157874-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885TLR8 51/4885SMN1; SMN2 3812/4885 |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885TLR8 51/4885SMN1; SMN2 3812/4885 |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885TLR8 51/4885SMN1; SMN2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.